Clinical trials
Chronic Liver Disease clinical trials
Below are recruiting chronic liver disease clinical trials, each written for real people, not researchers. We’re tracking 388 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06875128RecruitingPhase 2
Liver-directed chemo with standard chemo for breast cancer
This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.
Tampa, FloridaAges 18 years+ - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT07195149RecruitingPhase 3
Aspirin dose comparison after bypass surgery
This trial tests whether a lower dose of aspirin combined with another blood thinner (prasugrel) after bypass surgery is as safe and effective as a higher dose. It is for people with stable heart disease who are scheduled for bypass surgery and have not had a recent heart attack.
BialystokAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06224140Recruiting
Dialysis without heparin: a safety study
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
Marseille, Bouches du RhôneAges 18 years+ - NCT06793787Recruiting
AI and advanced imaging to guide treatment of borderline heart blockages
This study uses advanced CT scans and a special camera (OCT) to look at borderline blockages in heart arteries more closely. It aims to see if artificial intelligence can help decide which blockages need a stent and which can be treated with medicine alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06406244Recruiting
TEAS for chronic pain after liver surgery
This trial tests whether a gentle, needle-free electrical stimulation on certain points on the body (called TEAS) can help reduce chronic pain after liver surgery and improve long-term survival. It may be a good option if you are scheduled for a liver removal and want to explore non-drug pain relief.
ChengduAges 18–80 - NCT06396871Recruiting
Blood cell study in metabolic diseases
This study looks at blood cells and factors in people with metabolic diseases like fatty liver, prediabetes, or type 2 diabetes. It aims to better understand these conditions by comparing them with healthy volunteers.
Dresden, SaxonyAges 18 years+ - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
San Francisco, CaliforniaAges 3–13 - NCT05242315RecruitingPhase 4
Long-acting tacrolimus after liver transplant
This trial studies whether taking an extended-release form of tacrolimus (a medicine to prevent transplant rejection) after a liver transplant works well for people who are followed at the University of Alberta. It may help simplify dosing and monitor safety and effectiveness after transplant.
Edmonton, AlbertaAges 18 years+ - NCT07337785RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Wuhan, HubeiAges 18–70 - NCT07191561Recruiting
Liver fat and alcohol use disorder study
This trial looks at how the liver processes fat in people with alcohol use disorder. It may help find better ways to treat liver problems related to drinking.
Bethesda, MarylandAges 18–100 - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
San Francisco, CaliforniaAges 18 years+ - NCT06966908Recruiting
Managing hepatitis B in non-specialty hospital settings
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
Guangzhou, GuangdongAges Any age - NCT07751783Recruiting
Exercise program for cancer survivors
This trial helps people who have finished cancer treatment start a supervised exercise routine to improve their health. It tests whether a structured program with professional guidance is safe and helpful.
Kaohsiung, TaiwanAges 18–80 - NCT06916520RecruitingPhase 4
Reduced dose prasugrel alone after stent placement
This trial tests if a lower dose of prasugrel, taken alone (without aspirin), is safe and works well for people who have had a stent placed for chest pain or a heart attack. It might be an option for those who need to simplify their medication routine.
AmsterdamAges 18 years+ - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07249346RecruitingPhase 2
Preventing GVHD after stem cell transplant with three drugs
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT06280950RecruitingPhase 2
Lowering immunosuppression after liver transplant with everolimus
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
Phoenix, ArizonaAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic liver disease?
- Yes. Clin2 currently lists 388 recruiting chronic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.